Schneider K, Roller M, Kalberlah F, Schuhmacher-Wolz U
Forschungs- und Beratungsinstitut Gefahrstoffe, FoBiG GmbH, Werderring 16, 79098 Freiburg, Germany.
J Appl Toxicol. 2002 Jan-Feb;22(1):73-83. doi: 10.1002/jat.828.
Cancer risk estimates for oral uptake of polycyclic aromatic hydrocarbons (PAHs) currently are based on risk estimates for benzo[a]pyrene (BAP). The potency of PAH mixtures often is calculated using relative potency values (BAP equivalency factors). We used recent oral carcinogenicity studies with BAP and coal tar mixtures, as well as older studies for a critical reappraisal of the current practice. A literature survey identified several carcinogenicity studies with oral and dermal exposure and lung implantation that allow a direct comparison of the carcinogenic potency of pure BAP and PAH mixtures. Moreover, when the PAH composition of the mixture has been analysed, prediction of the potency of PAH mixtures by BAP equivalency factors could be compared with the observed PAH potency. The analysis indicates that BAP equivalency factors do not describe adequately the potency of PAH mixtures and lead to underestimations of carcinogenic potency in most cases. Evaluation of several studies with various PAH mixtures revealed that the potency ratio between pure BAP and the PAH mixture in the same assay is highly dependent on the exposure pathway and the target organ, therefore potency estimates for PAH mixtures should be derived separately for oral, dermal and inhalative exposure using data from studies with the relevant pathway. A cancer slope factor for oral PAH exposure was derived based on data from a recent feeding study with coal tar mixtures. By using incidence data for all exposure-related tumours, a slope factor for humans of 11.5 (human excess risk per oral lifetime exposure with 1 mg BAP kg(-1)day(-1) in a PAH mixture) was obtained. Our analysis led to the conclusion that the contribution of BAP to the carcinogenic potency of the mixture depends on the exposure pathway and type of cancer observed but is relatively constant for various PAH mixtures from industrial sources. Thus, the derived oral slope factor is recommended to be used for the risk assessment of PAH-contaminated soils.
目前,多环芳烃(PAHs)经口摄入的癌症风险评估是基于苯并[a]芘(BAP)的风险评估。PAH混合物的致癌效力通常使用相对效力值(BAP当量因子)来计算。我们利用最近关于BAP和煤焦油混合物的经口致癌性研究,以及早期研究对当前做法进行了批判性重新评估。文献调查确定了几项经口和皮肤暴露以及肺部植入的致癌性研究,这些研究使得能够直接比较纯BAP和PAH混合物的致癌效力。此外,当分析混合物的PAH组成时,可以将通过BAP当量因子预测的PAH混合物效力与观察到的PAH效力进行比较。分析表明,BAP当量因子不能充分描述PAH混合物的效力,并且在大多数情况下会导致致癌效力的低估。对多项不同PAH混合物研究的评估表明,在同一试验中纯BAP与PAH混合物之间的效力比高度依赖于暴露途径和靶器官,因此,应使用相关途径研究的数据,分别针对经口、皮肤和吸入暴露得出PAH混合物的效力估计值。基于最近一项煤焦油混合物喂养研究的数据得出了经口PAH暴露的癌症斜率因子。通过使用所有与暴露相关肿瘤的发病率数据,得出人类的斜率因子为11.5(PAH混合物中每经口终生暴露1 mg BAP kg⁻¹天⁻¹的人类超额风险)。我们的分析得出结论,BAP对混合物致癌效力的贡献取决于暴露途径和观察到的癌症类型,但对于来自工业源的各种PAH混合物而言相对恒定。因此,建议将得出的经口斜率因子用于PAH污染土壤的风险评估。